Equity
€795,636 ▲ 20.9%
LIBAGYN has made a profit without a break since 2009.
LIBAGYN
Lifetime
19 annual accounts with figures on one time axispeak €494,842 (2025)
€494,842▲ 6.2%
lowest -€17,490 (2008)
€297,283▲ 11.7%
peak €795,636 (2025)
€795,636▲ 20.9%
€300,703▼ 35.6%
peak 1 FTE (2019)
-not published
Board1 name since 2006
1 director
Documentsfilings and deeds
31-08-202631 days late
2025micro format
Dividend €160,000Equity from €658,353 to €795,636Debts from €466,721 to €300,703Cash from €186,583 to €348,518
Key points
from the 2025 annual accountsFilings
19 annual accounts since 2007
Ten of the last ten came late. The 2020 accounts came latest: 87 days after the end of the period.
Position in the sector
€297,283
Higher net result than 95% of companies in human health. Sector median €59,563 · 21,309 companies.
Checked score
Bankruptcy probability within 12 months
Financial strength
Score breakdown
Comparable companies, two years later
In July 2024, 31,386 companies had the same profile as LIBAGYN has now. Each dot stands for 79 companies, two years later.
93.4%
were still trading
6.0%
stopped another way
0.5%
went bankrupt
Another 0.1% stopped without a precise date, possibly only after those two years.
Test of the method
The method was tested on the 497,762 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 2.9% | 3.1% |
| 10 | 5.6% | 6.1% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 31,386 companies, not a prediction for LIBAGYN. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Recent changes
Registered office moved from Woluwe-Saint-Lambert to Watermael-Boitsfort
New registered office: avenue Delleur 13, 1170 Watermael-Boitsfort · Previous registered office: rue Solleveld 4, boite 9, 1200 Woluwe-Saint-Lambert · “exercice de la médecine en Belgique” (deed in French) · General meeting of 17-09-2026 · Gazette deed
Incorporation
published on 03-07-2006 · Gazette deed
First establishment
Solleveldstraat 4, Woluwe-Saint-Lambert
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| LIBAGYN Watermael-Boitsfort | €1.1m | €494,842 | 72.6% | - |
| maison medicale perspective Anderlecht | €1.0m | €515,607 | 92.9% | 5.7 |
| EPITOPE Woluwe-Saint-Lambert | €1.1m | €551,238 | 38.3% | - |
| DOCTEUR ALEXANDER JENNIGES Bullange | €1.1m | €501,263 | 84.6% | - |
| DOKTER VANDEWAL Bruges | €1.1m | €493,426 | 90.8% | - |
| DOKTER ANN GALMART Wetteren | €1.1m | €463,562 | 75.7% | - |
| Internal and Emergency Medicine Mettet | €1.2m | €464,597 | 35.3% | 5.1 |
These companies have the same main activity as LIBAGYN: general medical practice (NACE 86210). They are comparable in size and age: total assets between €1m and €1.2m, founded between 2004 and 2008.
Official details
Source: KBO- Status
- Active since 22-06-2006Normal situation
- Activity
- General medical practiceNACE 86210
- Joint committee
- 330.04Health institutions and services · annual accounts 2025
- Establishment unit
- 2.236.374.3921200 Woluwe-Saint-Lambert, since 14-06-2006
- Financial year end
- 31 December
- Peppol
- Not found in the Peppol Directory
Annual accounts 2025
- ≈ €760,000estimated
- €1.1m▼ 2.6%
- Employeeson 31-12-2025
- 1=
- Filing
- Filed on 31-08-2026
Insights on LIBAGYN
LIBAGYN files the micro format. That format states no turnover. The gross margin rose from €46,785 in 2007 to €494,842 in 2025.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about LIBAGYN
- What is the company number of LIBAGYN?
- The company number of LIBAGYN is 0881.998.828. The VAT number is the same number with BE in front: BE 0881.998.828.
- Where is LIBAGYN based?
- The registered office is at Delleurlaan 13, 1170 Watermael-Boitsfort.Company details
- What does LIBAGYN do?
- According to the KBO register, the main activity is general medical practice (NACE 86210).
- What is the legal form of LIBAGYN?
- LIBAGYN is a private limited company (BV).
- When was LIBAGYN founded?
- LIBAGYN was founded on 22-06-2006.
- Is LIBAGYN still active?
- Yes, LIBAGYN is an active enterprise in the KBO register.
- How many employees does LIBAGYN have?
- LIBAGYN had an average of 1 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- Which joint committee does LIBAGYN fall under?
- In its 2025 annual accounts, LIBAGYN states joint committee 330.04 (Health institutions and services).
- What is the turnover of LIBAGYN?
- The turnover in financial year 2025 is ≈ €760,000. This figure is estimated from the gross margin of €494,842 and 38 comparable companies (NACE 862). It probably lies between €660,000 and €950,000.
- Is LIBAGYN profitable?
- In financial year 2025, LIBAGYN made a profit of €297,283.
- Where can I find the annual accounts of LIBAGYN?
- LIBAGYN filed 19 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of LIBAGYN due?
- LIBAGYN must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.